Key Points
- Jennifer Michaelson sold 1,780 shares of Cullinan Therapeutics on Feb. 25 at an average price of $14.14 (part of a series of recent insider sales including 11,742 shares on Feb. 20), trimming her stake to 174,844 shares — a ~1.01% reduction valued at about $2.47 million.
- Cullinan (CGEM) traded at $16.08 (near its 52-week high of $16.39) with a market cap of roughly $950 million and a negative P/E; analysts maintain a Moderate Buy consensus and an average price target of $29.33 (range roughly $26–$33 from major firms).
Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) insider Jennifer Michaelson sold 1,780 shares of the company's stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $14.14, for a total transaction of $25,169.20. Following the completion of the sale, the insider directly owned 174,844 shares in the company, valued at approximately $2,472,294.16. The trade was a 1.01% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Jennifer Michaelson also recently made the following trade(s):
- On Tuesday, February 24th, Jennifer Michaelson sold 3,601 shares of Cullinan Therapeutics stock. The stock was sold at an average price of $14.47, for a total transaction of $52,106.47.
- On Monday, February 23rd, Jennifer Michaelson sold 1,752 shares of Cullinan Therapeutics stock. The shares were sold at an average price of $13.99, for a total value of $24,510.48.
- On Friday, February 20th, Jennifer Michaelson sold 11,742 shares of Cullinan Therapeutics stock. The shares were sold at an average price of $14.08, for a total value of $165,327.36.
- On Thursday, February 12th, Jennifer Michaelson sold 416 shares of Cullinan Therapeutics stock. The stock was sold at an average price of $12.03, for a total value of $5,004.48.
- On Thursday, January 22nd, Jennifer Michaelson sold 4,000 shares of Cullinan Therapeutics stock. The shares were sold at an average price of $12.30, for a total value of $49,200.00.
- On Friday, December 19th, Jennifer Michaelson sold 1,345 shares of Cullinan Therapeutics stock. The shares were sold at an average price of $10.01, for a total value of $13,463.45.
- On Thursday, December 18th, Jennifer Michaelson sold 2,898 shares of Cullinan Therapeutics stock. The stock was sold at an average price of $9.67, for a total value of $28,023.66.
- On Monday, December 15th, Jennifer Michaelson sold 995 shares of Cullinan Therapeutics stock. The shares were sold at an average price of $11.90, for a total value of $11,840.50.
- On Friday, December 12th, Jennifer Michaelson sold 2,148 shares of Cullinan Therapeutics stock. The shares were sold at an average price of $12.38, for a total transaction of $26,592.24.
Cullinan Therapeutics Price Performance
Shares of CGEM traded up $0.87 during trading hours on Friday, hitting $16.08. The stock had a trading volume of 187,657 shares, compared to its average volume of 714,596. The stock has a market capitalization of $949.95 million, a price-to-earnings ratio of -4.87 and a beta of -0.09. The company's fifty day moving average is $11.61 and its two-hundred day moving average is $9.35. Cullinan Therapeutics, Inc. has a 52 week low of $5.68 and a 52 week high of $16.39.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd increased its holdings in Cullinan Therapeutics by 62.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,696 shares of the company's stock valued at $28,000 after purchasing an additional 1,036 shares during the last quarter. Seven Fleet Capital Management LP acquired a new position in shares of Cullinan Therapeutics during the 4th quarter worth about $31,000. CWM LLC increased its stake in shares of Cullinan Therapeutics by 51.5% in the 4th quarter. CWM LLC now owns 3,876 shares of the company's stock valued at $40,000 after acquiring an additional 1,318 shares during the last quarter. Signaturefd LLC increased its stake in shares of Cullinan Therapeutics by 689.7% in the 4th quarter. Signaturefd LLC now owns 4,130 shares of the company's stock valued at $43,000 after acquiring an additional 3,607 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its position in shares of Cullinan Therapeutics by 44.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 8,182 shares of the company's stock valued at $62,000 after acquiring an additional 2,523 shares during the period. 86.31% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
A number of research firms have recently issued reports on CGEM. Zacks Research cut shares of Cullinan Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Thursday, February 19th. Guggenheim assumed coverage on Cullinan Therapeutics in a report on Monday, February 2nd. They set a "buy" rating and a $30.00 price target for the company. New Street Research set a $26.00 target price on Cullinan Therapeutics in a research note on Thursday, November 20th. Citigroup began coverage on shares of Cullinan Therapeutics in a report on Tuesday, February 17th. They set a "buy" rating and a $33.00 price objective on the stock. Finally, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Cullinan Therapeutics in a research note on Monday, December 29th. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $29.33.
Get Our Latest Analysis on CGEM
About Cullinan Therapeutics
(
Get Free Report)
Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
